Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits

Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits

Alzheimer's disease (AD) and Type 2 Diabetes Mellitus (T2DM) are two of the most prevalent diseases in the elderly population worldwide. A growing body of epidemiological studies suggest that people with T2DM are at a higher risk of developing AD. Likewise, AD brains are less capable of glucose...

Full description

Bibliographic Details
Main Authors:	Shreyasi Chatterjee, Amritpal Mudher
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-06-01
Series:	Frontiers in Neuroscience
Subjects:	insulin resistance tau proteins abeta oligomers synaptic dysfunction autophagy inflammation
Online Access:	https://www.frontiersin.org/article/10.3389/fnins.2018.00383/full

Similar Items

Non-Canonical Roles of Tau and Their Contribution to Synaptic Dysfunction
by: Giacomo Siano, et al.
Published: (2021-09-01)

The Roles of Lipid and Glucose Metabolism in Modulation of β-Amyloid, Tau, and Neurodegeneration in the Pathogenesis of Alzheimer disease
by: Naoyuki eSato, et al.
Published: (2015-10-01)

2015: which new directions for Alzheimer’s disease?
by: Xénia eLATYPOVA, et al.
Published: (2014-12-01)

Insulin-Mediated Changes in Tau Hyperphosphorylation and Autophagy in a Drosophila Model of Tauopathy and Neuroblastoma Cells
by: Shreyasi Chatterjee, et al.
Published: (2019-08-01)

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease
by: Liana G. Apostolova, et al.
Published: (2014-01-01)

Alternative neural circuitry that might be impaired in the development of Alzheimer disease
by: Jesus eAvila, et al.
Published: (2015-04-01)

Tau: The Center of a Signaling Nexus in Alzheimer’s Disease
by: Shahzad eKhan, et al.
Published: (2016-02-01)

Intersection of pathological tau and microglia at the synapse
by: Thomas Vogels, et al.
Published: (2019-07-01)

Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers
by: Hansen Wang, et al.
Published: (2017-06-01)

Naphthoquinone-tyrptophan reduces neurotoxic Aβ*56 levels and improves cognition in Alzheimer's disease animal model
by: R. Scherzer-Attali, et al.
Published: (2012-06-01)

Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model
by: Fernando Goñi, et al.
Published: (2018-01-01)

Tau oligomers: the toxic player at synapses in Alzheimer’s disease
by: Marcos Jair Guerrero-Munoz, et al.
Published: (2015-12-01)

Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus
by: Tony Valente, et al.
Published: (2010-01-01)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease
by: Lambracht-Washington D, et al.
Published: (2013-08-01)

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.
by: Reinert, Jochim
Published: (2018)

Intranasal insulin reverts central pathology and cognitive impairment in diabetic mother offspring
by: Juan Jose Ramos-Rodriguez, et al.
Published: (2017-08-01)

The Role of Long Noncoding RNAs in Diabetic Alzheimer’s Disease
by: Young-Kook Kim, et al.
Published: (2018-11-01)

Understanding the Pathophysiological Actions of Tau Oligomers: A Critical Review of Current Electrophysiological Approaches
by: Emily Hill, et al.
Published: (2020-08-01)

Formation of Toxic Oligomeric Assemblies of RNA-binding Protein: Musashi in Alzheimer’s disease
by: Urmi Sengupta, et al.
Published: (2018-10-01)

A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer’s Disease
by: Rubayat Islam Khan, et al.
Published: (2018-08-01)

Molecular Mechanisms of Cognitive Dysfunction following Traumatic Brain Injury
by: Kendall Rae Walker, et al.
Published: (2013-07-01)

Intracellular accumulation of amyloid-beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease
by: Thomas A Bayer
Published: (2010-03-01)

Synaptic activity and Alzheimer’s disease: a critical update
by: Davide eTampellini
Published: (2015-11-01)

Are tau aggregates toxic or protective in tauopathies?
by: Catherine M Cowan, et al.
Published: (2013-08-01)

Commentary: APP as a Mediator of the Synapse Pathology in Alzheimer's Disease
by: An Schreurs, et al.
Published: (2018-05-01)

The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease.
by: Paola eFlores-Rodríguez, et al.
Published: (2015-02-01)

TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia
by: Mauro Montalbano, et al.
Published: (2020-12-01)

Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy
by: Yingjian You, et al.
Published: (2019-02-01)

Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis
by: Botond Penke, et al.
Published: (2020-04-01)

Possible Modification of Alzheimer Disease by Statins in Midlife: Interactions with Genetic and Non-Genetic Risk Factors
by: Mitsuru eShinohara, et al.
Published: (2014-04-01)

Dendritic/Post-synaptic Tau and Early Pathology of Alzheimer’s Disease
by: Xiaomin Yin, et al.
Published: (2021-06-01)

Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation
by: Shweta Kishor Sonawane, et al.
Published: (2021-02-01)

EVOO Polyphenols Relieve Synergistically Autophagy Dysregulation in a Cellular Model of Alzheimer’s Disease
by: Manuela Leri, et al.
Published: (2021-07-01)

TAU OLIGOMERS AS DIRECT TARGETS FOR ALZHEIMER´S DIAGNOSIS AND NOVEL DRUGS
by: Leonardo eGuzman-Martinez, et al.
Published: (2013-10-01)

In vivo tau pathology is associated with synaptic loss and altered synaptic function
by: Emma M. Coomans, et al.
Published: (2021-02-01)

Immunotherapy to improve cognition and reduce pathological species in an Alzheimer’s disease mouse model
by: Krystal Herline, et al.
Published: (2018-06-01)

Modélisation des phases précoces de la maladie d’Alzheimer par transfert de gènes
by: Audrain, Mickaël
Published: (2016)

Amphiphysin I cleavage by asparagine endopeptidase leads to tau hyperphosphorylation and synaptic dysfunction
by: Xingyu Zhang, et al.
Published: (2021-05-01)

Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer's disease: A multi-electrode array study
by: Seon-Ah Chong, et al.
Published: (2011-12-01)

P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer’s disease
by: Kathleen M. Farmer, et al.
Published: (2020-08-01)